Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03966560
Other study ID # KAEK-2014/04-74
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date January 2014
Est. completion date April 2015

Study information

Verified date May 2019
Source Afyon Kocatepe University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Glaucoma is one of the leading causes of blindness worldwide that is a chronic public health problem. Unfortunately, glaucoma can be diagnosed when the disease reaches a certain level in today's conditions. The aim of this study was to investigate the diagnostic methods that can diagnose glaucoma before it reaches the advanced level and to identify pathophysiological processes. In this study, choroidal thickness was investigated in primary open-angle glaucoma cases and its correlations with OCT and multifocal ERG parameters were evaluated.


Description:

In this study, patients with primary open-angle glaucoma who have recently received a new diagnosis with healthy volunteers with age-matched groups were enrolled. All data from 49 glaucoma patients and 47 healthy volunteers were recorded and the study was completed. The study was carried out at the Afyon Kocatepe University Ophthalmology Department between January 2014 and April 2015. Routine ophthalmologic examinations of all participants were performed. Medical treatment was initiated on patients diagnosed with primary open-angle glaucoma. Intraocular pressures and visual acuities of all participants were recorded at baseline, at 1-month, at 3-month, and at 6-month. All participants underwent tests of multifocal electroretinography and the measurements of optic nerve head optical coherence tomography parameters and the choroidal thickness, at the same follow-ups. Visual acuities were measured by using the Snellen chart as the best corrected visual acuity. Intraocular pressures were measured by using applanation tonometry. Choroid thicknesses were also measured and recorded using EDI-OCT mode of optical coherence tomography device (Cirrus HD 4000, Carl Zeiss Meditec AG, Germany). Choroidal thicknesses were measured in three regions: fovea, 3mm nasal and temporal distances of the fovea. The mean of these three measurements was recorded as macular choroidal thickness. The same technician performed all multifocal electroretinography tests of the participants (Metrovision Monpack 3, Metrovision, France). Multifocal electroretinography tests were carried out from a distance of 33 cm using ERG-jet electrode, ground electrode, and a reference electrode. Electrical potential responses from 103 retina regions were recorded. Results were compared statistically and correlations were analyzed (SPSS 20.0, SPSS Inc. IL, USA).


Recruitment information / eligibility

Status Completed
Enrollment 96
Est. completion date April 2015
Est. primary completion date January 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 40 Years and older
Eligibility Inclusion Criteria for the glaucoma group:

- the best corrected visual acuity (BCVA) of 0.6 and above

- Intraocular pressure being above 21 mmHg

- Detection of open-angle by gonioscopy

- Detection of glaucomatous optic disc pitting by fundus examination

- Visual field defect in perimetry (Carl Zeiss Meditec AG, Germany)

Exclusion Criteria for the glaucoma group:

- A secondary cause of glaucoma

- Angle-closure in gonioscopic examination

- Corneal opacity or cataract at the level that may affect imaging, vitreous pathology

- Intravitreal hemorrhage that may affect fundus appearance, retinal pathology

- Chorioretinopathy, optic neuropathy, optic disc pathology, spherical refractive error of 6D and above, cylindrical refraction error of 3D and above and systemic diseases which may affect ocular blood flow

Inclusion Criteria for the healthy group:

- The best corrected visual acuity (BCVA) of 0.8 and above

Exclusion Criteria for the healthy group:

- Presence of systemic disease that may affect choroid blood flow

- Ocular conditions that may affect test measurements

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Brimonidine Tartrate
Brimonidine tartrate 0.15% 1 eye drop, every day for 6-months
Dorzolamide (as Dorzolamide Hydrochloride) 20 Mg/mL and Timolol (as Timolol Maleate) 5 Mg/mL Eye Drops
Dorzolamide and timolol fixed combination 2 eye drops, every day for 6 months
Brinzolamide/Timolol 10 MG/1 ML-5 MG/1 ML Ophthalmic Suspension
Brinzolamide and timolol fixed combination 2 eye drops, every day for 6 months
Travoprost and Timolol
Travoprost and Timolol fixed combination 1 eye drop, every day for 6 months
Bimatoprost and Timolol
Bimatoprost and Timolol fixed combination 1 eye drop, every day for 6 months
Latanoprost
Latanoprost 0.005% 1 eye drop, every day for 6 months

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Afyon Kocatepe University Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary Macular choroidal thickness measure Measuring macular choroidal thickness at baseline, at 1-month, at 3-month and at 6-month by using optical coherence tomography Baseline, 1-month, 3-month, 6-month
Primary Changes in multifocal electroretinography parameters (Amplitudes [nv/deg2] and impulse times [ms] of N1, N2 and P1 waves in Ring-1, Ring-2, Ring-3 and Ring-4) Comparison of the mean multifocal electroretinography parameters (Amplitudes [nv/deg2] and impulse times [ms] of N1, N2 and P1 waves in Ring-1, Ring-2, Ring-3 and Ring-4) at baseline, at 1-month, at 3-month and at 6-month Baseline, 1-month, 3-month, 6-month
Primary Changes in amplitudes of N1 wave in Ring-1, Ring-2, Ring-3 and Ring-4 [nv/deg2] Comparison of the mean amplitudes of N1 wave [nv/deg2] in Ring-1, Ring-2, Ring-3 and Ring-4) at baseline, at 1-month, at 3-month and at 6-month Baseline, 1-month, 3-month, 6-month
Primary Changes in amplitudes of N2 wave in Ring-1, Ring-2, Ring-3 and Ring-4 [nv/deg2] Comparison of the mean amplitudes of N2 wave [nv/deg2] in Ring-1, Ring-2, Ring-3 and Ring-4) at baseline, at 1-month, at 3-month and at 6-month Baseline, 1-month, 3-month, 6-month
Primary Changes in amplitudes of P1 wave in Ring-1, Ring-2, Ring-3 and Ring-4 [nv/deg2] Comparison of the mean amplitudes of P1 wave [nv/deg2] in Ring-1, Ring-2, Ring-3 and Ring-4) at baseline, at 1-month, at 3-month and at 6-month Baseline, 1-month, 3-month, 6-month
Primary Changes in impulse times of N1 wave in Ring-1, Ring-2, Ring-3 and Ring-4 [ms] Comparison of the mean impulse times of N1 wave [ms] in Ring-1, Ring-2, Ring-3 and Ring-4) at baseline, at 1-month, at 3-month and at 6-month Baseline, 1-month, 3-month, 6-month
Primary Changes in impulse times of P1 wave in Ring-1, Ring-2, Ring-3 and Ring-4 [ms] Comparison of the mean impulse times of P1 wave [ms] in Ring-1, Ring-2, Ring-3 and Ring-4) at baseline, at 1-month, at 3-month and at 6-month Baseline, 1-month, 3-month, 6-month
Primary Changes in P1/N1 ratio of N2 wave in Ring-1, Ring-2, Ring-3 and Ring-4 Comparison of the mean P1/N1 ratios of N2 wave in Ring-1, Ring-2, Ring-3 and Ring-4) at baseline, at 1-month, at 3-month and at 6-month Baseline, 1-month, 3-month, 6-month
Primary Changes in the mean optic nerve head optical coherence tomography parameters (Retinal nerve fiber layer thickness [micrometers], disc area [mm2], cup-to-disc ratios, cup volume [mm3], neuroretinal rim area [mm2]) Measuring optic nerve head optical coherence tomography parameters (Retinal nerve fiber layer thickness [micrometers], disc area [mm2], cup-to-disc ratios, cup volume [mm3], neuroretinal rim area [mm2]) at 1-month, at 3-month and at 6-month Baseline, 1-month, 3-month, 6-month
Primary Changes in the mean neuroretinal rim area [mm2]) Measuring neuroretinal rim area [mm2] at 1-month, at 3-month and at 6-month Baseline, 1-month, 3-month, 6-month
Primary Changes in the mean cup volume [mm3] Measuring cup volume [mm3] at 1-month, at 3-month and at 6-month Baseline, 1-month, 3-month, 6-month
Primary Changes in the mean cup-to-disc ratios Measuring cup-to-disc ratios at 1-month, at 3-month and at 6-month Baseline, 1-month, 3-month, 6-month
Primary Changes in the mean disc area [mm2] Measuring disc area [mm2] at 1-month, at 3-month and at 6-month Baseline, 1-month, 3-month, 6-month
Primary Changes in the mean retinal nerve fiber layer thickness [micrometers] Measuring retinal nerve fiber layer thicknesses [micrometers] at 1-month, at 3-month and at 6-month Baseline, 1-month, 3-month, 6-month
Secondary Best-corrected visual acuity measure Comparison of the mean best-corrected visual acuities at 1-month, at 3-month and at 6-month Baseline, 1-month, 3-month, 6-month
Secondary Intraocular pressure measure Measuring intraocular pressure at 1-month, at 3-month and at 6-month Baseline, 1-month, 3-month, 6-month
Secondary Correlations between choroidal thickness and other parameters Analyze correlations between changes of choroidal thicknesses and changes of other parameters during the study. Baseline, 6-month
See also
  Status Clinical Trial Phase
Completed NCT05044793 - A Clinical Study To Assess The Safety And Effectiveness Of The OMNI® Surgical System
Recruiting NCT06201455 - Evaluation of Phacogoniotomy in Medically-controlled POAG N/A
Recruiting NCT03369886 - The Relationship Between Macular OCTA and GCIPL and Their Combinational Index Using AI N/A
Active, not recruiting NCT04624698 - iStent Inject New Enrollment Post-Approval Study N/A
Recruiting NCT02679482 - Following Patients After Selective and Pascal Laser Trabeculoplasty for Treatment of Chronic Open-Angle Glaucoma N/A
Completed NCT02338362 - Inhaled Corticosteroids: Effect on Intraocular Pressure in Patients With Controlled Glaucoma Phase 4
Active, not recruiting NCT01430923 - Clinical Evaluation of Safety and Efficacy of Refrigeration Free Latanoprost N/A
Completed NCT01489670 - Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension N/A
Completed NCT00693485 - Safety and Effects of Brimonidine Intravitreal Implant in Patients With Glaucomatous Optic Neuropathy Phase 2
Completed NCT00753168 - Phase 1-2 Evaluation of OT-730 Eye Drops in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-Angle Glaucoma Phase 1/Phase 2
Completed NCT00051194 - A 6-week Safety & Efficacy Study of Combination Intraocular Pressure-lowering Therapy in Patients With Open-angle Glaucoma or Ocular Hypertension Phase 2
Recruiting NCT04920227 - Comparation of CLASS Combined With Phacoemulsification and CLASS Alone in the Treatment of Primary Open Angle Glaucoma N/A
Active, not recruiting NCT03868124 - Clinical Study Comparing Two Models of a Travoprost Intraocular Implant Phase 3
Completed NCT03267862 - Scleral Response to Intraocular Pressure (IOP) N/A
Recruiting NCT06066645 - Travoprost Intraocular Implant + iStent Infinite vs. iStent Infinite Alone Phase 3
Recruiting NCT04912362 - The Effectiveness of YAG Iridotomy in Preventing Peripheral Anterior Synechia After CLASS in Primary Open Angle Glaucoma N/A
Completed NCT04949802 - Glaucoma Surgery Using the ViaLase Laser System N/A
Recruiting NCT04038034 - Valuation of the Antioxidant and Neuroprotective Effects of CoQ10-MINIACTIVES® (COQUN® OS) in Patients Affected by Primary Open Angle Glaucoma N/A
Completed NCT04632329 - Negative Pressure Applied by the Equinox MPD for Severe Open Angle Glaucoma N/A
Completed NCT01215786 - Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma Phase 1